drugset / Trial / NCT01204840

Growth Hormone for Poor Responders in in Vitro Fertilization (IVF)

NCT01204840

Phase 2 Completed 38 enrolled Ottawa Fertility Centre EMD Serono · collab
RandomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine if growth hormone given 4 weeks before as well as during a cycle of in vitro fertilization will improve outcomes in women who have had previous failure with IVF treatment cycles using high doses of follicle stimulating medications and had a poor response (less than 6 follicles).

Timeline

Start
2010-09
Primary completion
2015-05
Completion
2015-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Somatropin Protein / enzyme biologic 3.33 mg Subcutaneous
Comparator Cetrorelix Other / unclassified 0.25 mg
Comparator Estradiol Other / unclassified 100 ug Other
Comparator Gonal-f Protein / enzyme biologic 412 iu
Comparator Luveris Protein / enzyme biologic 150 iu
Comparator Progesterone Other / unclassified 100 mg Other
Comparator human chorionic gonadotropin Protein / enzyme biologic 10000 iu